Odyssey Therapeutics, Inc. Common Stock · ODTX

Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026 Correlation between clinical efficacy and changes in inflammatory biomarkers, mucosal transcriptomic signatures, and histologic disease activity strengthens the previously shown clinical proof of concept for OD-001 Favorable tolerability profile and oral administration underscore the potential of OD-001 as a monotherapy and backbone for combination regimens in infl…

8-K · 2026-10-20 · 0001193125-26-425684

Corporate Presentation October 2026 Forward-looking statements and third-party information This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, but not limited to, statements regarding our business strategy; the future clinical development, efficacy, safety, and therapeutic potential of o…

8-K · 2026-10-20 · 0001193125-26-425684

EX-99.1 2 odtx-ex99_1.htm EX-99.1 Corporate Presentation September 2026 Confidential information, forward-looking statements, and third-party information This presentation (including any discussion that accompanies this presentation) contains highly confidential information regarding Odyssey Therapeutics, Inc. (the “Company,” “Odyssey,” “we,” or “us”) and its subsidiaries and may not be disclosed, copied, or distributed to any person other than the intended recipient, directly or indirectl…

8-K · 2026-09-09 · 0001193125-26-385477

EX-99.1 2 odtx-ex99_1.htm EX-99.1 EX-99.1 Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October Phase 2a combination trial of OD-001 with vedolizumab and Phase 2b monotherapy trial of OD-001 expected to initiate in 2H 2026 Cash on hand as of June 30, 2026 of $433.1M expected to fund operations into the second half…

8-K · 2026-08-04 · 0001193125-26-331512

EX-99.1 2 odtx-ex99_1.htm EX-99.1 Corporate Presentation June 2026 Confidential information, forward-looking statements, and third-party information This presentation (including any discussion that accompanies this presentation) contains highly confidential information regarding Odyssey Therapeutics, Inc. (the “Company,” “Odyssey,” “we,” or “us”) and its subsidiaries and may not be disclosed, copied, or distributed to any person other than the intended recipient, directly or indirectly, in…

8-K · 2026-06-23 · 0001193125-26-278581

EX-99.1 2 odtx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis Cash on hand as of March 31, 2026, together with net proceeds from the IPO, and concurrent private placement, of $464M expected to fund operations into …

8-K · 2026-06-17 · 0001193125-26-274291